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1 |  INTRODUCTION
Osteogenesis imperfecta (OI) is a hereditary connective- 
tissue disease with an incidence of 1:10,000– 20,000 births. 
It is characterized by various degrees of bone fragility and 
fractures, blue sclera, dentinogenesis imperfecta, and onset 
of hearing loss in young adulthood (Marini et al., 2017). 
The spectrum of clinical severity ranges from mild to severe, 
and the four classical categories proposed by Sillence et al., 
(1979) have recently been re- categorized into five (Mortier 
et al., 2019; Van Dijk & Sillence, 2014). OI type 1 is the mild-
est form characterized by straight limbs (non- deforming). 
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Abstract
Background: Osteogenesis imperfecta (OI) is a rare connective- tissue disorder char-
acterized by bone fragility. Approximately 90% of all OI cases are caused by vari-
ants in COL1A1 or COL1A2. Additionally, IFITM5 variants are responsible for the 
unique OI type 5. We previously analyzed COL1A1/2 variants in 22 Japanese fami-
lies with OI through denaturing high- performance liquid chromatography screening, 
but our detection rate was low (41%).
Methods: To expand the genotype- phenotype correlations, we performed a genetic 
analysis of COL1A1/2 and IFITM5 in 96 non- consanguineous Japanese OI probands 
by Sanger sequencing.
Results: Of these individuals, 54, 41, and 1 had type 1 (mild), type 2– 4 (moderate- to- 
severe), and type 5 phenotypes, respectively. In the mild group, COL1A1 nonsense 
and splice- site variants were prevalent (n = 30 and 20, respectively), but there were 
also COL1A1 and COL1A2 triple- helical glycine substitutions (n = 2 and 1, respec-
tively). In the moderate- to- severe group, although COL1A1 and COL1A2 glycine 
substitutions were common (n = 14 and 18, respectively), other variants were also 
detected. The single case of type 5 had the characteristic c.- 14C>T variant in IFITM5.
Conclusion: These results increase our previous detection rate for COL1A1/2 vari-
ants to 99% and provide insight into the genotype- phenotype correlations in OI.
K E Y W O R D S
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Type 2 is perinatally lethal, and is characterized by the pres-
ence of intrauterine fractures (perinatally lethal). Type 3 is 
the most severe form in which patients survive the neonatal 
period. It presents with multiple fractures and progressive 
skeletal deformities (progressively deforming). Patients with 
type 4 OI show a severity intermediate between those of type 
1 and 3 patients. They present with varying degrees of bone 
deformity (moderately deforming). Type 5 is characterized 
by moderate- to- severe bone fragility. It is unique in the sense 
that it presents with ossification of the interosseous mem-
brane, radial head dislocation, subphyseal metaphyseal radi-
odense bands, and hyperplastic callus formation (Glorieux 
et al., 2000).
Type I collagen is a fundamental component of the ex-
tracellular matrices of the bone, skin, tendon, and other 
connective- tissue types. It consists of two α1 (I) and one α2 
(I) polypeptide chains encoded by COL1A1 and COL1A2, re-
spectively. Each chain has triple- helical domains composed 
of Gly- X- Y tripeptide repeats and is assembled into a het-
erotrimer. The helical domain is flanked by globular N- and 
C- terminal propeptides. The assembly proceeds from the C- 
terminal toward the N- terminal. Type I procollagen is secreted 
from the rough endoplasmic reticulum (ER), and then the 
C- and N- terminal propeptides are cleaved off. Most genetic 
defects affecting bone metabolism cause the recessive forms 
of OI: (i) posttranslational modification (CRTAP, P3H1, 
and PPIB), (ii) processing and crosslinking (SERPINH1, 
FKBP10, PLOD2, and BMP1), (iii) osteoblast differentiation 
and function (SP7, TMEM38B, WNT1, CREB3L1, SPARC, 
SEC24D, and MBTPS2), or (iv) bone mineralization and re-
sorption (PLS3 and SERPINF1) (Marini et al., 2017; Etich 
et al., 2020). Nevertheless, dominant COL1A1 and COL1A2 
changes occur in ~90% of OI patients (Marini et al., 2017). 
Reduced levels of wildtype collagens, as in COL1A1 hap-
loinsufficiency, cause a mild OI phenotype. In contrast, 
structural abnormalities develop mainly in the more severe 
forms of OI. Substitution of glycine especially with serine 
within the Gly- X- Y tripeptide repeat region is the most com-
mon triple- helical assembly disruption in type I procollagen 
(Lindahl et al., 2015; Marini et al., 2007; Rauch et al., 2010). 
OI type 5 is caused by the heterozygous variant c.- 14C>T 
in the 5′- UTR of IFITM5. This gene encodes interferon- 
induced transmembrane protein- 5, which is involved in early 
bone mineralization (Cho et al., 2012; Semler et al., 2012). 
Several studies have reported that this particular variant is 
the third most common change found in OI patients (Bardai 
et al., 2016; Liu et al., 2017; Patel et al., 2015).
OI is mainly caused by variants in type I collagen; 
however, the genetic analysis of OI is laborious and time- 
consuming because type I collagen genes are large (COL1A1 
and COL1A2 have 51 and 52 exons within 18 and 38 kb, re-
spectively) and have no apparent variant hotspots. Limited 
published data are available on the molecular diagnosis of OI 
in Japan (Kanno et al., 2018; Ohata et al., 2019). We previ-
ously reported six COL1A1 and three COL1A2 variants in 22 
families with OI through Sanger sequencing and heteroduplex 
screening using denaturing high- performance liquid chroma-
tography (DHPLC) (Kataoka et al., 2007). Nevertheless, the 
detection rate was low (41%) and changes in IFITM5 were 
not analyzed. In the present study, we investigated the gen-
otype and phenotype spectra of a larger group of Japanese 
patients with OI.
2 |  METHODS
2.1 | Editorial policies and ethical 
considerations
All the procedures in this study were performed in accord-
ance with the 1964 Helsinki Declaration and 2003 Japanese 
Ethical Guidelines for Clinical Research, as well as their 
later amendments. This study was approved by the Ethics 
Committee of Okayama University Hospital (No. 1701- 038). 
Written informed consent for the genetic analyses and pub-
lication was obtained from the probands and/or their legal 
guardians.
2.2 | Subjects
Whole- blood or DNA samples were obtained between March 
2010 and January 2020 from non- consanguineous Japanese 
OI probands in our facility and 41 other nationwide facilities 
for the genetic analysis of COL1A1, COL1A2, and IFITM5. 
Patients were clinically diagnosed based on bone fragility, re-
current fractures, and bone deformity with or without family 
history by their attending physicians, and the diagnoses were 
afterward confirmed by one of the authors with sufficient 
experience (KH or HTa). Clinical information, including 
age, sex, family history, Sillence classification, extraskeletal 
features (blue sclera, dentinogenesis imperfecta (DI), and 
hearing loss), and radiographs, was also obtained. Subjects 
were classified into three age- based categories namely, child 
(0– 12 years), adolescent (13– 18 years), and adult (19 years 
and above). Where available, baseline bone mineral density 
(BMD) (before bisphosphonate treatment) and Z- score of the 
lumbar spine evaluated through dual- energy X- ray absorpti-
ometry were also collected. OI types 1– 4 were re- classified 
as “mild OI (OI type 1)” and “moderate- to- severe OI (OI 
types 2– 4)” because OI classification depends on the amount 
of clinical information available and is somewhat subjective 
(Bardai et al., 2016). The number and frequency of fractures 
are likely to be affected by the patient's age, treatment method 
(i.e., modified by bisphosphonate therapy), and also depends 
on the patient's or their family's recollection, especially in 
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elder patients. Categories were determined according to the 
presence (moderate- to- severe OI) or absence (mild OI) of 
any deformity in the lower extremities as a simpler sever-
ity indicator (Van Dijk & Sillence, 2014). Bone fragility was 
defined as 1) prenatal bowing, shortening, or fractures of 
long bones: 2) minor postnatal trauma or unexplained bone 
fractures.
2.3 | Sanger sequencing
Genomic DNA was extracted from blood samples with 
a genomic DNA Extraction Kit (Qiagen) by following the 
manufacturer's instructions. Previously, PCR primers cor-
responding to all the exons or >30- bp regions flanking the 
exon- intron junctions of COL1A1 and COL1A2 have been 
used (Kataoka et al., 2007; Körkkö et al., 1998). From these 
previously tested primers, 16 and 22 primer pairs, spanning 
multiple exons, were selected for COL1A1 and COL1A2, re-
spectively. Primers for IFITM5 were designed. The primer sets 
and PCR conditions are shown in Data S1. Amplicons were 
analyzed on a 3% agarose gel and purified using a QIAquick 
Purification Kit (Qiagen). Sequencing was performed in a 
BigDye Terminator v. 3.1 Cycle Sequencing Kit and the ABI 
Prism 310 Genetic Analyzer (Applied Biosystems). Raw 
sequencing data are available upon request. First, IFITM5 
was sequenced in individuals clinically suspected of being 
OI type 5. COL1A1 and COL1A2 were then sequenced 
(exons 1– 51 and 1– 52, respectively). Sequence reads were 
aligned with reference sequences from GenBank (COL1A1: 
NG_007400.1; COL1A2: NG_007405.1; and IFITM5: 
NG_032892.1). Nucleotides were numbered according to 
the cDNA references (COL1A1: NM_000088.3; COL1A2: 
NM_000089.3; and IFITM5: NM_001025295.3). Amino 
acid residues were numbered according to the protein ref-
erences (COL1A1: NP_000079.2; COL1A2: NP_000080.2; 
and IFITM5: NP_001020466.1). Non- synonymous or 
splice- site variants were considered putative mutations if 
they were not listed in the Single Nucleotide Polymorphism 
(SNP) database or 1,000 Genomes Project. Variant patho-
genicity was analyzed with PolyPhen- 2 (http://genet ics.
bwh.harva rd.edu/pph2/), PROVEAN (http://prove an.jcvi.
org/index.php), Mutation Taster (http://www.mutat ionta 
ster.org/), and Human Splicing Finder (http://www.umd.be/
HSF3/HSF.shtml) (Adzhubei et al., 2010; Choi et al., 2012; 
Schwarz, Rödelsperger, Schuelke, & Seelow, 2010; Desmet 
et al., 2009). All the variants were classified according to 
the ACMG variant interpretation guideline (Richards et al., 
2015). Allele frequencies of novel missense variants were 
examined in the genome aggregation database (gnomAD, 
https://gnomad.broad insti tute.org/). The novelty was defined 
according to the Osteogenesis Imperfecta Variant Database 
(http://www.le.ac.uk/ge/colla gen/), and any causal variant 
was searched from COL1A1 exon 1 and progress through 
COL1A2 exon 52. If the variant had previously been reported 
and corresponded to the phenotypes, the remaining exons 
were not sequenced. The proband variant data were depos-
ited in the Global Variome shared LOVD database (https://
datab ases.lovd.nl/). A segregation analysis of the proband 
relatives was optionally conducted.
2.4 | Statistical analysis
Data are presented as median and range. Either, a Pearson's 
chi- square test or a Fisher's exact test was applied to cat-
egorical data and the Mann– Whitney U test was used on 
continuous variables. p < 0.05 was considered a significant 
difference (Wasserstein et al., 2019). All the analyses were 
run in Stata v. 14.2 (StataCorp).
3 |  RESULTS
3.1 | Clinical characteristics
The present study included 96 probands (52 males and 44 
females) from 96 unrelated families. Of these, 44 had a fam-
ily history of OI. The median age at the time of analysis was 
4.0 years (range, 0– 52 years). Fifty- four (56.3%) were classi-
fied as the mild OI group, 41 (42.7%) were in the moderate- 
to- severe OI group, and1(1.0%) with the ossification of the 
interosseous membrane and radial head dislocation was cat-
egorized as OI type 5. Eighteen in the mild group and 20 in 
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Family history 31/54 12/41 1/1
OI, osteogenesis imperfecta.
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the moderate- to- severe group were aged ≤1 years. All infan-
tile patients without extra- skeletal manifestation and family 
history showed moderate- to- severe OI. The scleral color was 
reported in 76 cases. Nearly all of the mild OI patients had 
blue sclera, compared with only 71.4% of the moderate- to- 
severe OI patients (p = 0.001). Dental status was reported 
for 45 cases, and nine from each group presented with DI 
(p = 0.064). Hearing status was reported for 27 cases. Four 
comparatively older cases (11 y, 22 y, 24 y, and 38 y) in the 
mild OI group had a hearing impairment. The BMD Z- scores 
of the lumbar spine in bisphosphonate- naïve were lower in 
the moderate- to- severe OI group (n = 5) than in the mild OI 
group (n = 17) (p = 0.001) (Figure S1) (Tables 1 and 2).
3.2 | Genotype- phenotype correlation
All but one of the probands had a pathogenic or likely patho-
genic variant. There were 60, 21, and 1 variants of COL1A1, 
COL1A2, and IFITM5 identified, respectively (Table 3). 
Thirty- six novel variants were discovered. Ten variants were 
detected two or three times. All the probands and affected 
family members with the same variant had similar OI severi-
ties. Nearly all the cases with COL1A1 splice- site or nonsense 
variants (97.8%) had blue sclera compared with 78.9% of the 
cases harboring COL1A1 or COL1A2 glycine substitutions. 
DI was present in 40.0% of the splice- site or nonsense vari-
ants, whereas 50.0% of the cases with the missense variants 
presented with DI. All three cases with COL1A1 C- terminal 
propeptide missense variants lacked blue sclera. The OI type 
5 proband had the variant c.- 14C>T in IFITM5. A segrega-
tion analysis was performed on 32 families (21 in the mild 
OI group, 10 in the moderate- to- severe OI group, and 1 in the 
OI type 5 group), and the identified variants were validated. 
Most of the affected family members were patients’ parent, 
but some offspring, siblings, grandparents, or cousins were 
also affected.
In the mild OI group, COL1A1 nonsense and splice- site 
variants were found in 30 and 20 probands, respectively. 
Triple- helical domain glycine substitutions were detected in 
three probands. We identified a novel de novo noncanonical 
COL1A1 splice- site variant c.696+4delA (IVS9 +4delA) 
(Patients ID 4) as likely pathogenic. The patient had no other 
variant in COL1A1, COL1A2, or IFITM5, and unaffected 
parents did not carry this variant. The COL1A2 C- terminal 
propeptide variant c.3883T>C (p.Ser1295Pro) was classified 
as a variant of uncertain significance (VUS). It has previ-
ously been reported as benign/likely benign (rs757449082), 
and had a very low allele frequency in East Asian popula-
tions (0.0006). In the presented study, variants causing mild 
OI were distributed throughout COL1A1 (Figure 1).
In the moderate- to- severe OI group, COL1A1 splice- 
site variants were identified in three cases (c.697- 1G>A 
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(IVS9 −1G>A), c.1668+1G>A (IVS24 +1G>A), and 
c.4248+1G>A (IVS50 +1G>A). Triple- helical domain gly-
cine substitutions were found in 32 cases. COL1A1 C- terminal 
propeptide missense variants were present in three cases, and 
in- frame insertion or deletion within the triple- helical do-
mains was found in two. The COL1A1 C- terminal propeptide 
variant c.4328C>T (p.Ala1443Val) has previously been de-
posited as a VUS(rs1131692326). Its allele frequency has not 
been reported, but it has recently been cited as the causative 
variant for OI type 3 (Li, et al., 2019). Glycine- to- serine sub-
stitutions in the triple- helical domain occurred at the highest 
frequency (COL1A1, n = 11; COL1A2, n = 6). Substitutions 
to branched or charged amino acids (valine, aspartic acid, and 
arginine) were found at the N- terminal portion of COL1A1 
(n  =  2), whereas such variants were scattered throughout 
COL1A2 (n  =  12). Taken as a whole, the variants causing 
moderate- to- severe OI were skewed toward the C- terminal of 
COL1A1 and COL1A2 (Figure 1).
4 |  DISCUSSION
The present study showed genotypic and phenotypic correla-
tions among non- consanguineous Japanese OI patients. To 
the best of our knowledge, our study population constitutes 
one of the largest Japanese OI populations assessed to date. 
Sanger sequencing identified type I collagen variants in 99% 
of the individuals tested. The detection rate for type I collagen 
mutation ranges from 60% to 100% in various OI populations 
(Ho Duy et al., 2016; Lin et al., 2015; Lindahl et al., 2015; 
Mohd Nawawi et al., 2018). Bardai et al. have reported 598 
individuals with a typical OI phenotype (mild, moderate- to- 
severe, and type 5 in 43%, 52%, and 5%, respectively), and all 
the patients that were classified as mild OI had COL1A1 or 
COL1A2 variants, whereas only 85% did in the moderate- to- 
severe OI group (Bardai et al., 2016). Recessive OI usually 
manifests the more severe phenotype. Therefore, the detec-
tion rate may be affected by the ethnicity and consanguinity 
of the study population, and the disease severity (Fernandes 
et al., 2020; Mrosk et al., 2018). Ohata et al., (2019) have 
conducted comprehensive genetic analyses through targeted 
next- generation sequencing in 53 Japanese OI patients but 
only detected variants in COL1A1, COL1A2, and IFITM5. 
In fact, autosomal recessive diseases are very rare in Japan 
(e.g., phenylketonuria has a rate of 1:125,000, and cystic 
fibrosis a rate of 1:350,000), so recessive OI patients are 
scarcely reported (Aoki & Wada, 1988; Takeyari et al., 2018; 
Yamashiro et al., 1997). We believe that Sanger sequenc-
ing may still be applicable in the genophenotypic analysis 
of non- consanguineous OI populations (Mrosk et al., 2018). 
Moreover, our detection rate in the present study was supe-
rior to that of the previous one (Kataoka et al., 2007) because, 
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familiar with OI, and DHPLC screening was omitted in case 
of false negatives (Phadke, 2015; Stephen et al., 2014). One 
proband presenting with the specific features of OI type 5 
harbored the characteristic c.- 14C>T variant in IFITM5. 
Whereas other IFITM5 variants have been reported in some 
OI patients, a distinct phenotype of OI type 5 is exclusively 
observed in patients with this variant (Mohd Nawawi et al., 
2018; Rodriguez Celin et al., 2018).
Blue sclera occurred more frequently in the mild OI group 
than the moderate- to- severe group. There was no significant 
difference between the two groups in terms of DI incidence. 
COL1A1 splice- site or nonsense variants were the most 
closely correlated with the blue sclera, whereas there was no 
association between this genotype and DI. The latter results 
could be explained by the relative lack of information on the 
dental status of the test population because its members were 
comparatively young. Approximately 90% of the OI type 1 
probands had blue sclera, and ~70% of the OI type 3 or 4 pro-
bands manifested this trait; whereas ~10% of OI type 1 had 
DI and ~60% of OI type 3 and 4 cases presented with the den-
tal aberrations (Bardai et al., 2016; Lindahl et al., 2015; Patel 
et al., 2015). Hearing loss usually develops between the sec-
ond and fourth decades of OI patients. Nevertheless, the re-
lationship between this symptom and the molecular data has 
not been fully elucidated (Swinnen et al., 2011; Hald et al., 
2018). In the present study, four individuals presented with 
hearing impairment in adolescence and young adulthood, but 
the number of cases was insufficient for the assessment of 
genotypic associations.
Glycine is the only residue small enough to fit into the ste-
rically restricted space at the helical center. Most of the gly-
cine substitutions produced moderate- to- severe phenotypes, 
but some resulted in the mild form. Our results corroborate 
those previously reported (Lindahl et al., 2015; Rauch et al., 
2010; Zhytnik et al., 2017). Lindahl et al. have reported that 
32% of the type 1 OI cases are caused by qualitative vari-
ants in COL1A1 and COL1A2. Phenotypes resulting from 
COL1A1 missense variants may be more severe than those 
caused by COL1A2 variants because 75% of the procolla-
gen molecules in the heterozygotes of COL1A1 mutants are 
expected to have ≥1 mutant pro- α1(I) chain. In contrast, in 
the case of COL1A2 variants, only 50% of the molecules 
presumably contain the mutant pro- α2(I) chain (Brodsky 
& Persikov, 2014). Glycine substitutions to branched or 
charged amino acids are highly disruptive to helix stability 
and are mainly confined to the region near the N- terminal 
of COL1A1. On the other hand, they are observed through-
out COL1A2 (Marini et al., 2007; Rauch et al., 2010). These 
characteristics are consistent with our findings. In contrast, 
substitutions by small amino acids (cysteine, alanine, and 
serine) produce variable outcomes. For example, the variant 
c.3505G>A (p.Gly1169Ser) in COL1A1 exon 47 is reported 
seventeen times in the OI variant database, and four of these 
are described as OI type 1. Familial cases of this variant pres-
ent with significant phenotype diversity, ranging from mild 
to severe (Liu et al., 2016). A recent study has reported that 
familial cases with haploinsufficiency have lower phenotypic 
variability, whereas those with structural abnormality are 
more likely to show higher phenotypic variability (Zhytnik 
et al., 2020). Our familial cases also showed a similar ten-
dency; this may reflect the fact that the majority of patients 
exhibited a mild phenotype. The effects of genetic, epigene-
tic, environmental, or other unidentified factors on the same 
change and the corresponding variability in its clinical sever-
ity remain unknown. Several dozens in- frame insertions or 
deletions in the Gly- X- Y tripeptide repeat region are reported 
F I G U R E  1  Variant spectra of COL1A1 and COL1A2. Symbols above the box represent the variants in the mild OI group. Symbols below the 
box represent the variants in the moderate- to- severe OI group. Aligned symbols represent the same variant
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in the OI variant database, most of which are tripeptide or any 
multiple of three amino acids. Duplication or deletion of one 
or two Gly- X- Y triplets shift the register of collagen chains 
and prevent the incorporation of the mutant chains into the 
collagen trimer, leading to lethal or severe OI (Cabral et al., 
2003). All but one of single or double amino acid insertion 
or deletion also show moderate- to- severe phenotypes, similar 
to our findings.
Splice- site variants that cause exon skipping within the 
triple- helical domain can maintain the reading frame and 
lead to shifted alignment, impaired triple helix structures, 
and severe phenotypes (Marini et al., 2007). Conversely, vari-
ants resulting from intron retention or cryptic- site activation 
may cause premature termination codons and produce milder 
phenotypes. In a study on COL1A1 splice variants, all indi-
viduals with IVS(X)- 1G>A acceptor site transitions showed 
the OI type 1 phenotype (Schleit et al., 2015). Guanine is 
the first nucleotide in most COL1A1 exons and particularly 
in the triple- helical domains. This transition creates a new 
splice acceptor 1 nt downstream and produces a frameshift 
and a mild OI phenotype (Byers, 2014). This hypothesis may 
plausibly predict the effects of splice– acceptor- site variants. 
However, we found the COL1A1 splice- site variant c.697- 
1G>A (IVS9 −1G>A) in an individual with bone defor-
mities. Furthermore, certain IVS(X)- 1G>A acceptor- site 
variants are described as type 4 in the OI- variant database. 
On the other hand, splice– donor- site variants may result in 
different, less predictable, OI severities as well.
The C- terminal propeptide domains of procollagen are 
essential for the folding of the three proα(I)- chains and 
their secretion from the rough ER (Barnes et al., 2019; 
Doan et al., 2020). The crystalline structure of the C- 
terminal propeptide trimer resembles a flower and has a 
stalk, base, and petal region. It harbors a conserved amino 
acid sequence (Malfait et al., 2014; Sharma et al., 2017). 
Symoens et al. have reported 30 unique C- terminal pro-
peptide defects (Symoens et al., 2014). The missense vari-
ants in COL1A1 may induce a more severe OI phenotype 
than those in COL1A2, which would be consistent with 
the results of our study. The COL1A2 c.3883C>T (p.Ser-
1295Pro, rs757449082) variant was classified as VUS, 
which has two interpretations (either likely benign with 
osteogenesis imperfecta or benign with Ehlers- Danlos 
Syndrome Arthrochalasia Type 2). However, we think that 
this variant could cause a mild OI phenotype. Furthermore, 
all three probands with this type of variant (moderate- 
to- severe group, Patients IDs 18, 20, and 21) had normal 
sclera. When other study results are also considered, only 
6/19 (32%) of such patients present with the blue sclera 
(Barnes et al., 2019; Li, Mao, et al., 2019; Lu et al., 2014; 
Symoens et al., 2014). Although the bluish color of the 
sclera may fade with age in moderate- to- severe OI patients 
(Sillence et al., 1993), there may be a correlation between 
COL1A1 C- terminal propeptide missense variants and nor-
mal sclera.
The present study had several limitations. First, most of 
the COL1A1 and COL1A2 variants in this study population 
were probably skewed toward the mild phenotype. Second, 
our method may have overlooked monoallelic, biallelic, or 
digenic causative variants; several studies have reported pa-
tients with double pathogenic variants (Ackermann & Levine, 
2017; Ho Duy et al., 2016; Mohd Nawawi et al., 2018; Mrosk 
et al., 2018; Takagi et al., 2015). Third, we did not perform 
functional analyses on the proteins, mRNAs, or cDNAs iso-
lated from cultured fibroblasts. Such assays detect quantita-
tive and/or qualitative defects and may help elucidate variants 
within the clinical spectrum (Li et al., 2019; Van Dijk et al., 
2012).
The present study described the variant spectra of COL1A, 
COL1A2, and IFITM5 among 96 OI probands, thereby elu-
cidating the genotypic and phenotypic correlations in OI. 
This sample population constitutes one of the largest ones 
analyzed in Japan, so that our detection rate for type I col-
lagen variants have improved relative to that of our previous 
report. Consequently, we found that C- terminal propeptide 
missense variants of the α1 (I) chain may be related to the 
normal sclera.
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